Interferon-alfa, interferon-lambda and hepatitis C.

O'Brien TR

doi:10.1038/ng.453

Interferon-alfa, interferon-lambda and hepatitis C.

Nature Genetics, 13 Sep 2009, 41(10):1048-1050
https://doi.org/10.1038/ng.453 PMID: 19749756

This is a comment on "Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C." Nat Genet. 2009 Oct;41(10):1105-9. This is a comment on "IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy." Nat Genet. 2009 Oct;41(10):1100-4.

Abstract

No abstract provided.

Full text links

Read article at publisher's site: https://doi.org/10.1038/ng.453

References

Articles referenced by this article (15)

NIH Consensus. NIH Consens. State Sci. Statements 19, 1–46 (2002).
Global epidemiology of hepatitis C virus infection.
Shepard CW, Finelli L, Alter MJ
Lancet Infect Dis, (9):558-567 2005
MED: 16122679
Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection.
McHutchison JG, Lawitz EJ, Shiffman ML, Muir AJ, Galler GW, McCone J, Nyberg LM, Lee WM, Ghalib RH, Schiff ER, Galati JS, Bacon BR, Davis MN, Mukhopadhyay P, Koury K, Noviello S, Pedicone LD, Brass CA, Albrecht JK, Sulkowski MS; IDEAL Study Team, Afdhal N, Al-Osaimi A, Balart L, Bennett M, Bernstein D, Bini E, Black M, Bloomer J, Bonilla H, Box T, Boyer T, Brau N, Brown K, Brown R, Bruno C, Cassidy W, Chung R, Clain D, Crippin J, Dalke D, Davis C, Davis G, Felizarta F, Firpi-Morell R, Flamm S, Franco J, Freilich B, Gibas A, Godofsky E, Gordon F, Gross J, Harrison S, Herrera J, Herrine S, Herring R, Hu KQ, Israel J, Jacobson I, Joshi S, Khalili M, Kilby A, King J, King P, Koch A, Krawitt E, Kugelmas M, Kwo P, Lambiase L, Lebovics E, Levin J, Levine R, Lidofsky S, Lucey M, Mailliard M, Marsano L, Martin P, McGarrity T, Mikolich D, Morgan T, Mullen K, Munoz S, Nelson D, Nunes F, Nyberg A, Oh S, Pandya P, Pauly MP, Peine C, Perillo R, Poleynard G, Poordad F, Post A, Poulos J, Pound D, Rabinovitz M, Ravendhran N, Ready J, Reddy R, Reindollar R, Reuben A, Rossaro L, Rothman L, Rubin R, Rustgi V, Ryan M, Schmidt W, Semon W, Sepe T, Sherman K, Sjogren M, Sjogren R, Smith C, Stein L, Strauss R, Swaim M, Szabo G, Thurn J, Tong M, Vierling J, Wu G, Yapp R, Younes Z, Zaman A
N Engl J Med, (6):580-593 2009
MED: 19625712
Chronic hepatitis C virus infection: genotyping and its clinical role.
Bowden DS, Berzsenyi MD
Future Microbiol, (1):103-112 2006
MED: 17661689
IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy.
Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML, Bassendine M, Spengler U, Dore GJ, Powell E, Riordan S, Sheridan D, Smedile A, Fragomeli V, Muller T, Bahlo M, Stewart GJ, Booth DR, George J
Nat Genet, (10):1100-1104 2009
MED: 19749758
Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C.
Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, Nakagawa M, Korenaga M, Hino K, Hige S, Ito Y, Mita E, Tanaka E, Mochida S, Murawaki Y, Honda M, Sakai A, Hiasa Y, Nishiguchi S, [...] Mizokami M
Nat Genet, (10):1105-1109 2009
MED: 19749757
Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance.
Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, Heinzen EL, Qiu P, Bertelsen AH, Muir AJ, Sulkowski M, McHutchison JG, Goldstein DB
Nature, (7262):399-401 2009
MED: 19684573
Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1.
Conjeevaram HS, Fried MW, Jeffers LJ, Terrault NA, Wiley-Lucas TE, Afdhal N, Brown RS, Belle SH, Hoofnagle JH, Kleiner DE, Howell CD; Virahep-C Study Group
Gastroenterology, (2):470-477 2006
MED: 16890601
IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex.
Kotenko SV, Gallagher G, Baurin VV, Lewis-Antes A, Shen M, Shah NK, Langer JA, Sheikh F, Dickensheets H, Donnelly RP
Nat Immunol, (1):69-77 2002
MED: 12483210
IL-28, IL-29 and their class II cytokine receptor IL-28R.
Sheppard P, Kindsvogel W, Xu W, Henderson K, Schlutsmeyer S, Whitmore TE, Kuestner R, Garrigues U, Birks C, Roraback J, Ostrander C, Dong D, Shin J, Presnell S, Fox B, Haldeman B, Cooper E, Taft D, Gilbert T, [...] Klucher KM
Nat Immunol, (1):63-68 2002
MED: 12469119

Show 5 more references (10 of 15)

Citations & impact

Impact metrics

Citations

Jump to Citations

Citations of article over time

Alternative metrics

Altmetric item for https://www.altmetric.com/details/1833623

Altmetric
Discover the attention surrounding your research
https://www.altmetric.com/details/1833623

Article citations

Fibrosis and Hepatocarcinogenesis: Role of Gene-Environment Interactions in Liver Disease Progression.
Banerjee A, Farci P
Int J Mol Sci, 25(16):8641, 08 Aug 2024
Cited by: 1 article | PMID: 39201329 | PMCID: PMC11354981
Review
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
IFNL4 Genotype Frequencies in Asian Populations Support Shorter Duration Therapy with Sofosbuvir-Based Hepatitis C Virus Regimens to Increase the Number Cured.
O'Brien TR, Lee MH, Wilson E, Kottilil S
J Interferon Cytokine Res, 43(9):435-438, 22 Jun 2023
Cited by: 2 articles | PMID: 37347978 | PMCID: PMC10517314
Free full text in Europe PMC
Meeting Overview: Interferon Lambda-Disease Impact and Therapeutic Potential.
O'Brien TR, Young HA, Donnelly RP, Prokunina-Olsson L
J Interferon Cytokine Res, 39(10):586-591, 17 Apr 2019
Cited by: 3 articles | PMID: 30998425 | PMCID: PMC6767859
Free full text in Europe PMC
Immune checkpoint blockade and interferon-α in melanoma.
Rafique I, Kirkwood JM, Tarhini AA
Semin Oncol, 42(3):436-447, 14 Feb 2015
Cited by: 20 articles | PMID: 25965362 | PMCID: PMC4429252
Review Free full text in Europe PMC
Incidence and cost of treatment-emergent comorbid events in insured patients with chronic hepatitis C virus infection: a retrospective cohort study.
Sapra S, Chang E, Broder MS, L'Italien G
BMC Health Serv Res, 14:429, 24 Sep 2014
Cited by: 2 articles | PMID: 25249187 | PMCID: PMC4263056
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC

Go to all (48) article citations

Data

Data behind the article

This data has been text mined from the article, or deposited into data resources.

SNPs

(1 citation) dbSNP - rs8099917

Funding

Funders who supported this work.

Intramural NIH HHS (1)

Grant ID: Z01 CP005782
2 publications

Search life-sciences literature (45,103,589 articles, preprints and more)

Interferon-alfa, interferon-lambda and hepatitis C.

Abstract

Full text links

References

NIH Consensus. NIH Consens. State Sci. Statements 19, 1–46 (2002).

Global epidemiology of hepatitis C virus infection.

Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection.

Chronic hepatitis C virus infection: genotyping and its clinical role.

IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy.

Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C.

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance.

Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1.

IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex.

IL-28, IL-29 and their class II cytokine receptor IL-28R.

Citations & impact

Impact metrics

Citations of article over time

Alternative metrics

Article citations

Fibrosis and Hepatocarcinogenesis: Role of Gene-Environment Interactions in Liver Disease Progression.

IFNL4 Genotype Frequencies in Asian Populations Support Shorter Duration Therapy with Sofosbuvir-Based Hepatitis C Virus Regimens to Increase the Number Cured.

Meeting Overview: Interferon Lambda-Disease Impact and Therapeutic Potential.

Immune checkpoint blockade and interferon-α in melanoma.

Incidence and cost of treatment-emergent comorbid events in insured patients with chronic hepatitis C virus infection: a retrospective cohort study.

Data

Data behind the article

SNPs

Similar Articles

Predictive value of interferon-lambda gene polymorphisms for treatment response in chronic hepatitis C.

IL28B: A new wager in the skyline of hepatitis C virus infection.

IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy.

Role of interleukin-28B polymorphism as a predictor of sustained virological response in patients with chronic hepatitis C treated with triple therapy: a systematic review and meta-analysis.

Funding

Intramural NIH HHS (1)

Partnerships & funding

Search life-sciences literature (45,103,589 articles, preprints and more)

Interferon-alfa, interferon-lambda and hepatitis C.

Abstract

Full text links

References

NIH Consensus. NIH Consens. State Sci. Statements 19, 1–46 (2002).

Citations & impact

Impact metrics

Citations of article over time

Alternative metrics

Article citations

Data

Data behind the article

SNPs

Similar Articles

Funding

Intramural NIH HHS (1)﻿

Partnerships & funding

Intramural NIH HHS (1)